Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Umberto Peretti

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5063861160. Sources: OpenAlex.

Their work

Papers
20 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 6 papers · 2022: 1 paper · 2023: 4 papers · 2024: 3 papers · 2025: 1 paper

Papers 20

  1. Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life. Last author DOI 10.1016/j.dld.2024.06.025↗
  2. Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ctro.2024.100778↗
  3. Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.dld.2023.07.033↗
  4. A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants. Co-author DOI 10.1016/j.pan.2024.09.006↗
  5. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA… Co-author DOI 10.1007/s00280-023-04585-w↗
  6. The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis. Co-author DOI 10.1007/s12029-023-00923-6↗
  7. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  8. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  9. Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1016/j.ctrv.2022.102357↗
  10. Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. First author DOI 10.1007/s00280-020-04190-1↗
  11. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants. Co-author DOI 10.1016/j.ctrv.2021.102262↗
  12. Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.dld.2020.06.006↗
  13. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
  14. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  15. Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.688889↗
  16. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00280-020-04047-7↗
  17. Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. Co-author DOI 10.1016/j.ctrv.2018.10.013↗
  18. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreati… Co-author DOI 10.1016/j.ejca.2018.07.007↗
  19. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Co-author DOI 10.1016/s2468-1253(18)30196-1↗
  20. The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective. First author DOI 10.4103/eus.eus_62_17↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michele Reni · 19 shared papers, 2017–2025 · strength 2.53
  2. Marina Macchini · 17 shared papers, 2018–2025 · strength 2.31
  3. Giulia Orsi · 14 shared papers, 2020–2025 · strength 2.05
  4. Stefano Cascinu · 11 shared papers, 2021–2025 · strength 1.66
  5. Massimo Falconi · 6 shared papers, 2018–2024 · strength 0.74
  6. Silvia Matilde Zanon · 7 shared papers, 2017–2021 · strength 0.70
  7. Anna Maria Militello · 5 shared papers, 2021–2023 · strength 0.65
  8. Guido Giordano · 5 shared papers, 2021–2025 · strength 0.64
  9. Ilario Giovanni Rapposelli · 5 shared papers, 2021–2025 · strength 0.64
  10. Giampaolo Tortora · 5 shared papers, 2021–2023 · strength 0.55
  11. Michèle Milella · 5 shared papers, 2021–2023 · strength 0.55
  12. Luca Gianni · 5 shared papers, 2018–2021 · strength 0.47
  13. Letizia Procaccio · 3 shared papers, 2023–2025 · strength 0.46
  14. Monica Niger · 4 shared papers, 2021–2023 · strength 0.44
  15. Gianpaolo Balzano · 4 shared papers, 2018–2024 · strength 0.42
  16. Domenico Tamburrino · 3 shared papers, 2020–2024 · strength 0.40
  17. Mario Scartozzi · 3 shared papers, 2021–2024 · strength 0.39
  18. Andrea Spallanzani · 3 shared papers, 2021–2024 · strength 0.39
  19. Ingrid Garajová · 3 shared papers, 2021–2024 · strength 0.39
  20. Luca Faloppi · 2 shared papers, 2024–2025 · strength 0.37
  21. Marta Chiaravalli · 4 shared papers, 2018–2021 · strength 0.37
  22. Paolo Passoni · 3 shared papers, 2018–2024 · strength 0.36
  23. Elisa Giommoni · 3 shared papers, 2021–2023 · strength 0.35
  24. Silvia Bozzarelli · 3 shared papers, 2021–2023 · strength 0.35
  25. Lisa Salvatore · 3 shared papers, 2021–2023 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.